Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;186(4):327-332.
doi: 10.1667/RR14437.1. Epub 2016 Sep 2.

Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition

David A Gewirtz  1 , Moureq Alotaibi  1   2 , Vasily A Yakovlev  3 , Lawrence F Povirk  1
Affiliations
Review

Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition

David A Gewirtz et al. Radiat Res. 2016 Oct.

Abstract

Inhibitors of poly(ADP-ribose) polymerase (PARP) are clinically used as single-agent therapy for tumors with BRCA1 or BRCA2 mutations. One approach to expanding the use of PARP inhibitors to a wider range of tumors is to combine them with cytotoxic chemotherapy or radiotherapy. Preclinical studies in experimental animals and tumor cells in culture indicate that PARP inhibition modestly sensitizes most tumor cells to ionizing radiation. Studies of cell behavior after these combined treatments show that radiosensitization is manifested predominantly in an increase in prolonged growth arrest and senescence, with little or no contribution from apoptosis. The secretory phenotype associated with senescence can target these tumor cells for immune surveillance, and therefore increased senescence can effectively contribute to tumor control. However, the possible recovery of senescent cells and re-entry into cell cycle after prolonged arrest also needs to be considered. Such recovery could lead to tumor recurrence, yet may not be reflected in short-term assays commonly used to assess radiosensitization.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Divergent outcomes of radiation-induced senescence and its enhancement by PARP inhibitors. Senescence, at least initially, is maintained by signaling from unrepaired DSBs. PARP inhibitors block SSB repair, thus increasing the chances of collision with a replication fork to generate additional DSBs. PARP inhibition also promotes misjoining of these DSBs by NHEJ, which may be undetectable and inconsequential until the cell attempts to divide, at which point dicentric and other aberrant chromosomes could induce mitotic catastrophe. Alternatively, senescence, through the senescence-associated secretory phenotype, may promote cell death by triggering immune surveillance. However, some senescent cells may ultimately repair persistent damage or develop tolerance to it, and again begin to proliferate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sugo N, Niimi N, Aratani Y, Masutani M, Suzuki H, Koyama H. Decreased PARP-1 levels accelerate embryonic lethality but attenuate neuronal apoptosis in DNA polymerase beta-deficient mice. Biochem Biophys Res Commun. 2007;354:656–61. - PubMed
    1. Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther. 2014;349:408–16. - PMC - PubMed
    1. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21. - PubMed
    1. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res. 2005;52:109–18. - PubMed
    1. Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K, et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev. 2010;36:566–75. - PubMed

Publication types

MeSH terms

Substances